The progress of CML involves not only the BCR-ABL1/STAT5/MYC/PIM signaling but also other survival pathways such as JNK, ERK 1/2, p38MAPK or AKT (Ren, 2005; McCubrey et al., 2008). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.